Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

PurposeLimited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxelas first-line chemotherapy for patients with mCRPC who were treated in our institution.Materials and MethodsWe retrospectively identified patients with mCRPC and a Karnosfky performance statusof 60% or greater treated with docetaxelon any schedule as first-line chemotherapy between 2008 and 2013. The primary end point was a comparison of median overall survival (OS) according to age in this population. Secondary end points were comparisons of the rates of severe toxicities, prostate-specific antigen(PSA) decline of 50% or greater, and time to progression (TTP). Results were stratified by three age groups: younger than 65 years, 65 to 74 years, and 75 years or older.ResultsAmong the 197 patients included, 68 (34%) were younger than 65 years, 85 (43%) were 65 to 74 y...